New cancer drug IPH4502 enters first human tests
NCT ID NCT06781983
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will also look for early signs that it might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IPH4502 (a drug that targets Nectin-4, a protein on some cancer cells)
- What this could lead to
- If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for people with advanced cancers that have Nectin-4.
- What could go wrong
- This is a very early, first-in-human Phase 1 trial with only 145 participants. The drug may not be safe or effective, and side effects are unknown. Many early cancer drugs do not advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy Cancer Institute
Villejuif, 94805, France
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Massachusetts General Hospital - Boston
Boston, Massachusetts, 02114, United States
-
Mount Sinai Tisch Cancer Center
New York, New York, 10029, United States
-
NEXT Oncology - Dallas
Dallas, Texas, 75039, United States
-
NEXT Oncology - Virginia
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a dual protein blocker shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?